For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Nice Ltd. (NICE) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Gem · Gem Score +56 (−100…+100 Quality+Value blend) · Quality 57 · Value 56 · Sentiment -46 (timing only, not weighted) · Composite fair value $227.73 vs $98.04 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Nice Ltd.
NICE NASDAQNice Ltd. Sponsored ADR represents shares of NICE Ltd., an Israel-based enterprise software company focused on AI-powered cloud platforms for customer engagement and financial crime and compliance. The company operates primarily through two business segments: Customer Engagement and Financial Crime and Compliance. In customer engagement, NICE delivers CXone and related applications that support contact centers and digital interaction channels with capabilities such as call routing, self-service, workforce engagement, and analytics to optimize customer experience and operational efficiency. In financial crime and compliance, it provides embedded-AI solutions that help financial institutions detect and prevent money laundering, fraud, and trading abuses, while supporting regulatory reporting and surveillance. NICE also offers digital evidence management and investigation tools for public safety and justice agencies. Incorporated in 1986 and headquartered in Ra’anana, Israel, Nice Ltd. Sponsored ADR gives global investors exposure to a technology provider serving enterprises, financial institutions, and public sector organizations across the United States, Europe, the Middle East, Africa, and Asia-Pacific.
Price Overview The data point you'd notice
The headline on this page reads like a bargain: a profitable enterprise software incumbent with zero debt, $379M of cash, roughly a 12% free-cash-flow yield, trading near 14x trailing earnings against a sector median P/E of 143.8x. The valuation lens grades it Undervalued.
Then you look at the last four quarters of margin:
quarter revenue operating margin net margin 2025-09-30 $732.0M 22.0% 19.8% 2025-12-31 $786.5M 22.4% 19.1% 2026-03-31 $768.6M 16.5% 6.1% 2026-06-30 $782.3M 13.3% 10.6%
Operating margin fell from 22% to 13% in two quarters, and net margin from 19% to the 6–11% range. Revenue did not do this — revenue is flat-to-up. The trailing P/E is low because it still carries two pre-collapse quarters in the numerator.
What it usually means
A low multiple on earnings that just fell is not a discount; it is a lag. The honest test is to re-strike the multiple against the current run rate rather than the trailing one, and see whether the price still looks cheap.
Re-striking the multiple
On the latest quarter annualised — about $3,129M of revenue, 61.4M diluted shares:
scenario EPS P/E at $98 worth at a plain 15x collapse persists (net 10.6%) $5.40 18.1x $81 partial recovery (net 15%) $7.64 12.8x $115 back to FY2025 (net 20.8%) $10.60 9.2x $159
At today's earnings power you are paying 18x, not 14x — a full multiple for a business growing single digits. On a 15x multiple the persists-case is worth $81, below the current price. The stock also sits only 15% above its $85 EPV no-growth floor, which is the value of the business assuming it never grows again.
Read across those anchors and the market is implying roughly 40% odds that the margin collapse is temporary. That is not panic. It is a considered discount that leans toward "this is the new normal."
The topline underneath it
Growth is real but slower than the trailing figures suggest. Comparing like for like — first half 2026 against first half 2025 — revenue grew +8.7% ($1,426.9M to $1,550.9M). The annual path is +15.0% (FY23→FY24), then +7.7% (FY24→FY25), then ~8.7%. So one hard step-down, then a plateau.
The complication is that the category is compounding around 12%. Growing at 8.7% into a market growing 12% is share loss, and part of the reported growth is acquisition-assisted rather than organic.
The case for, and against
For: the balance sheet is genuinely distinctive — no debt, net cash, self-funding, with buybacks running above stock compensation and the diluted share count down from 66.9M to 61.4M. Net margin sits 13.1pp above the sector median and ROE 15.8% against 9.3%, so even post-collapse this is a better-than-average operator. If the margin drop is integration cost, deal amortisation or deliberate reinvestment, it reverses, and $115–138 is reachable.
Against: if the margin drop is price concession to defend seats against AI-native entrants, it is not a cost problem at all — it is the topline verdict appearing one line lower, and it does not reverse on management's decision. Gross margin has also slipped four straight years, 68.7% to 65.1%, which is consistent with either explanation.
Practical implication
The upside here does not come from the market misjudging the decline. On the numbers, the market has judged it roughly correctly. Everything rests on one unresolved question: is the H1-2026 margin collapse transitory or structural?
That makes this a conditional position rather than a valuation opportunity. The resolver is the next print and the segment detail behind it — specifically whether gross margin erosion is mix (acquired revenue at lower margin, roughly neutral) or price (concessions, which is the bear case confirmed). Those look identical on the income statement and mean opposite things.
At $98 the expected value across those two outcomes is close to the price itself. The asymmetry only becomes interesting below $85, where the no-growth floor is paid for and any recovery is free.
The data point you'd notice
The headline on this page reads like a bargain: a profitable enterprise software incumbent with zero debt, $379M of cash, roughly a 12% free-cash-flow yield, trading near 14x trailing earnings against a sector median P/E of 143.8x. The valuation lens grades it Undervalued.
Then you look at the last four quarters of margin:
| quarter | revenue | operating margin | net margin |
|---|---|---|---|
| 2025-09-30 | $732.0M | 22.0% | 19.8% |
| 2025-12-31 | $786.5M | 22.4% | 19.1% |
| 2026-03-31 | $768.6M | 16.5% | 6.1% |
| 2026-06-30 | $782.3M | 13.3% | 10.6% |
Operating margin fell from 22% to 13% in two quarters, and net margin from 19% to the 6–11% range. Revenue did not do this — revenue is flat-to-up. The trailing P/E is low because it still carries two pre-collapse quarters in the numerator.
What it usually means
A low multiple on earnings that just fell is not a discount; it is a lag. The honest test is to re-strike the multiple against the current run rate rather than the trailing one, and see whether the price still looks cheap.
Re-striking the multiple
On the latest quarter annualised — about $3,129M of revenue, 61.4M diluted shares:
| scenario | EPS | P/E at $98 | worth at a plain 15x |
|---|---|---|---|
| collapse persists (net 10.6%) | $5.40 | 18.1x | $81 |
| partial recovery (net 15%) | $7.64 | 12.8x | $115 |
| back to FY2025 (net 20.8%) | $10.60 | 9.2x | $159 |
At today's earnings power you are paying 18x, not 14x — a full multiple for a business growing single digits. On a 15x multiple the persists-case is worth $81, below the current price. The stock also sits only 15% above its $85 EPV no-growth floor, which is the value of the business assuming it never grows again.
Read across those anchors and the market is implying roughly 40% odds that the margin collapse is temporary. That is not panic. It is a considered discount that leans toward "this is the new normal."
The topline underneath it
Growth is real but slower than the trailing figures suggest. Comparing like for like — first half 2026 against first half 2025 — revenue grew +8.7% ($1,426.9M to $1,550.9M). The annual path is +15.0% (FY23→FY24), then +7.7% (FY24→FY25), then ~8.7%. So one hard step-down, then a plateau.
The complication is that the category is compounding around 12%. Growing at 8.7% into a market growing 12% is share loss, and part of the reported growth is acquisition-assisted rather than organic.
The case for, and against
For: the balance sheet is genuinely distinctive — no debt, net cash, self-funding, with buybacks running above stock compensation and the diluted share count down from 66.9M to 61.4M. Net margin sits 13.1pp above the sector median and ROE 15.8% against 9.3%, so even post-collapse this is a better-than-average operator. If the margin drop is integration cost, deal amortisation or deliberate reinvestment, it reverses, and $115–138 is reachable.
Against: if the margin drop is price concession to defend seats against AI-native entrants, it is not a cost problem at all — it is the topline verdict appearing one line lower, and it does not reverse on management's decision. Gross margin has also slipped four straight years, 68.7% to 65.1%, which is consistent with either explanation.
Practical implication
The upside here does not come from the market misjudging the decline. On the numbers, the market has judged it roughly correctly. Everything rests on one unresolved question: is the H1-2026 margin collapse transitory or structural?
That makes this a conditional position rather than a valuation opportunity. The resolver is the next print and the segment detail behind it — specifically whether gross margin erosion is mix (acquired revenue at lower margin, roughly neutral) or price (concessions, which is the bear case confirmed). Those look identical on the income statement and mean opposite things.
At $98 the expected value across those two outcomes is close to the price itself. The asymmetry only becomes interesting below $85, where the no-growth floor is paid for and any recovery is free.
Price History (1 Year)
Revenue & Net Income Trend
This company does not file structured financial statements with the U.S. SEC, so quarterly figures aren't available from our filings-based data engine. Annual figures shown here come from the sources that do cover it.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 9.67
Total Equity: $3.88B
Shares: 63,323,000
Total Debt: $0.00
Cash: $379.39M
EBITDA: $844.80M
Total Debt: $0.00
Cash: $379.39M
Revenue: $2.95B
Revenue: $2.95B
Revenue: $2.95B
Total Equity: $3.88B
Tax Rate: 13.1%
Equity: $3.88B
Total Debt: $0.00
Cash: $379.39M
Current Liabilities: $887.63M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $3.88B
Shares: 63,323,000
Shares: 63,323,000
CapEx: -$18.92M
Shares: 63,323,000
Stock Price: $101.24
Net Income: $612.10M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 20, 2026 12:59pm (48d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.9B | $2.2B | $2.4B | $2.7B | $2.9B |
| Cost of Revenue | $624.5M | $683.7M | $768.2M | $909.5M | $989.3M |
| Gross Profit | $1.3B | $1.5B | $1.6B | $1.8B | $2.0B |
| Operating Expenses | $1.0B | $1.2B | $1.2B | $1.3B | $1.3B |
| Operating Income | $263.9M | $335.2M | $435.2M | $546.0M | $645.8M |
| Net Income | $199.6M | $265.1M | $336.5M | $439.5M | $612.1M |
| EBITDA | $448.0M | $511.7M | $602.6M | $751.0M | $844.8M |
| EPS | $3.15 | $4.17 | $5.32 | $6.97 | $9.82 |
| EPS (Diluted) | $2.98 | $4.00 | $5.11 | $6.76 | $9.67 |
Balance Sheet (Annual)
Last updated: Aug 20, 2026 12:59pm (48d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $378.7M | $529.6M | $511.8M | $481.7M | $379.4M |
| Total Current Assets | $2.3B | $2.4B | $2.3B | $2.5B | $1.4B |
| Total Assets | $4.7B | $4.9B | $5.1B | $5.3B | $5.1B |
| Current Liabilities | $1.3B | $1.1B | $1.1B | $1.5B | $887.6M |
| Long-Term Debt | $429.3M | $455.4M | $457.1M | $0 | — |
| Total Liabilities | $1.9B | $1.8B | $1.8B | $1.7B | $1.2B |
| Total Equity | $2.8B | $3.1B | $3.4B | $3.6B | $3.9B |
| Retained Earnings | $1.7B | $1.9B | $2.3B | $2.7B | $3.3B |
Cash Flow (Annual)
Last updated: Aug 20, 2026 12:59pm (48d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $461.8M | $479.7M | $561.4M | $832.6M | $716.5M |
| Capital Expenditure | -$24.8M | -$31.9M | -$29.2M | -$35.0M | -$18.9M |
| Free Cash Flow | $437.0M | $447.8M | $532.2M | $797.7M | $697.6M |
| Acquisitions (net) | — | — | -$415.2M | -$64.8M | -$856.1M |
| Net Debt Issued / (Repaid) | -$177.3M | -$20.1M | -$2.6M | -$192.1M | -$460.0M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$73.2M | -$144.9M | -$288.4M | -$369.2M | -$488.9M |
| Net Change in Cash | -$63.6M | $154.4M | -$19.8M | -$28.3M | -$103.0M |
Growth Trends (YoY %)
Last updated: Aug 20, 2026 12:59pm (48d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +13.5% | +9.0% | +15.0% | +7.7% |
| Gross Profit Growth | +15.5% | +7.5% | +13.4% | +7.1% |
| Operating Income Growth | +27.0% | +29.9% | +25.4% | +18.3% |
| Net Income Growth | +32.8% | +26.9% | +30.6% | +39.3% |
| EBITDA Growth | +14.2% | +17.8% | +24.6% | +12.5% |
Dividend History (Last 20)
Last updated: Aug 20, 2026 12:59pm (48d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2017-02-23 | $0.16 | — | — | — |
| 2016-11-18 | $0.16 | — | — | — |
| 2016-08-11 | $0.16 | — | — | — |
| 2016-05-19 | $0.16 | — | — | — |
| 2016-02-22 | $0.16 | — | — | — |
| 2015-11-06 | $0.16 | — | — | — |
| 2015-08-07 | $0.16 | — | — | — |
| 2015-05-18 | $0.16 | — | — | — |
| 2015-02-13 | $0.16 | — | — | — |
| 2014-11-13 | $0.16 | — | — | — |
| 2014-08-08 | $0.16 | — | — | — |
| 2014-05-22 | $0.16 | — | — | — |
| 2014-02-13 | $0.16 | — | — | — |
| 2013-11-07 | $0.16 | — | — | — |
| 2013-08-20 | $0.16 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-02 02:03| Case | Growth | Margin | Fair value | vs price ($98.04) |
|---|---|---|---|---|
| Bull — recovery | +18% | 15.9% | $178.06 | +82% |
| Base — stabilizes | +12% | 13.9% | $129.59 | +32% |
| Bear — keeps slipping | +6% | 11.8% | $92.11 | -6% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-10 20:04The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Starting from the raw tape: NICE has compounded revenue from $1.92B (2021) to $2.95B (2025), a 13.6% CAGR, with operating income more than doubling ($264M → $646M) and op margin expanding from 13.7% to 21.9%. FCF of $697.6M on a $5.73B market cap is a ~12% FCF yield, and the balance sheet carries zero debt against $379M cash — so the "overpaid for scale, struggling to de-lever" bear narrative from the fallen-angel framing is factually wrong; there is no debt load to de-lever. That is a material error in the market-narrative module that should not be carried forward.
The quarterly trajectory is the actual concern. Sequential revenue is flatlining ($732M → $786M → $769M → $782M) and, more importantly, net margin collapsed from ~19% in H2-2025 to 6-10% in H1-2026. TTM NI of ~$425M vs 2025 annual NI of $612M implies the last two quarters ran roughly $170M below the prior run-rate on the bottom line — that's a real earnings-quality question the synthesis composite ($217 fair value, +141% upside) is glossing over. If you annualize the last two quarters ($130M NI × 2 = $260M) the P/E jumps from 14x to ~22x on depressed earnings, and the FCF number becomes the only thing holding the valuation story together. Whether the H1-2026 margin compression is one-time integration/restructuring or structural AI-driven pricing pressure is the entire thesis, and no model here actually resolves it.
The synthesis verdict of $217 fair value is not credible — it's using historical growth/margins that the last two prints just broke. The Market Forces "value trap" call is directionally more honest but overstates the case: a debt-free, 65% gross margin business at 8x EV/EBITDA and 12% FCF yield is not obviously a trap, it's a compressed multiple with an unresolved margin question. The thesis-evaluation score of -6 (essentially neutral) is the most defensible read of the mess. Insider activity is genuinely neutral — small option exercises and one 70k-share award, no meaningful open-market selling or buying to tiebreak. Contrarian pushback on my own skepticism: if H1-2026 margin compression is M&A-related amortization or a one-time charge (plausible given FCF held up at $697M while GAAP NI dropped), then 2027 normalized earnings power is closer to $550-600M and the stock at 10x that is genuinely cheap.
I partially dissent from the "fair value" synthesis — the $217 target is fantasy, but the stock at $98 with 12% FCF yield, no debt, and 13% historical revenue CAGR is more likely undervalued than fairly valued, contingent on the H1-2026 margin dip proving transitory. Fair value in a "margin normalizes to 18-20%" scenario is $130-150 (12-14x normalized $10 EPS); fair value in a "margins permanently reset to 10%" AI-commoditization scenario is $70-80. Current price splits the difference and slightly favors the bear case. I'd rate this a cheap option on margin recovery, not a table-pounder — need one more quarterly print to confirm whether Q1/Q2 2026 was integration noise or the new normal. The FCF-to-NI divergence ($697M FCF vs sub-$500M TTM NI trajectory) is the single most important number to reconcile and no model here did the work.
GPT Reading
At $98, NICE looks mispriced on the cheap side, and the raw numbers are better than the “structural decline” story. On a trailing twelve-month basis through 2026-06-30, revenue is about $3.07B, up roughly 12% versus the prior TTM base, which is actually faster than the 2025 full-year growth rate of 8%. Gross margin is still 65.1%, operating margin 18.5%, and net margin 13.9%, all perfectly healthy for an established application software vendor. More importantly, the valuation is extremely low for that profile: about 2.0x sales, 6.8x EV/EBITDA, 1.6x book, and 14.2x TTM earnings, with a net cash balance sheet and no debt. For a business that has grown annual revenue from $1.92B in 2021 to $2.95B in 2025 and is still growing double digits on the latest TTM view, that is not a normal software multiple; it is a discounted industrial multiple applied to a software asset.
The biggest thing that stands out is cash generation versus price. Even using only the latest annual cash flow statement, NICE produced $716.5M of operating cash flow and $697.6M of free cash flow on $2.95B of revenue, a roughly 23.6% FCF margin. Against a $5.73B market cap, that is an FCF yield around 12%. Capex is trivial at $18.9M, so this is not fake cash flow flattered by underinvestment. The balance sheet is also real support: $379.4M of cash, zero debt, and $3.88B of equity. That combination matters because it means the market is not being asked to fund an uncertain turnaround or a levered roll-up. Even if growth cools from low teens to high single digits, a debt-free software business with mid-60s gross margin and high-teens operating margin should not need heroics to justify more than 2x revenue.
The apparent contradiction is the weak-looking recent earnings line. TTM net income is only about $425.5M if you sum the last four quarters, which is below the 2025 annual net income of $612.1M despite higher revenue. Quarterly net margin also swung from 19.8% and 19.1% in 2025-09 and 2025-12 to just 6.1% and 10.6% in 2026-03 and 2026-06. That deserves respect. But I do not think it invalidates the stock; it mainly tells me reported earnings have become noisier than the business model. The revenue line did not break — it went from $732.0M to $786.5M to $768.6M to $782.3M, a stable upward band rather than a collapse. When revenue is holding near $3.1B annualized, gross margin remains 65%, and annual free cash flow was nearly $700M, I am more inclined to treat the earnings compression as something to investigate rather than blindly extrapolate into permanent deterioration. The market seems to have extrapolated.
The best bear case is that the market is correctly sniffing out a business whose economics have peaked. If AI and hyperscaler competition are commoditizing contact-center software, then the key warning sign would be exactly what we see here: revenue still growing for now, but profitability deteriorating first as pricing power weakens and sales or R&D spend rises to defend share. The drop from 2025 full-year operating income of $645.8M to a TTM operating margin of 18.5% also points in that direction. And while the cash flow history is strong, I only have the latest annual cash flow statement, not TTM cash flow through June, so I cannot prove that the near-$700M FCF level held during the margin slump. If TTM free cash flow has rolled over materially alongside net income, then the stock is less “cheap software compounder” and more “value trap with delayed cash-flow recognition.” That is the strongest argument against my bullish read.
What would change my mind is straightforward. If the next couple of quarters show revenue growth falling from the current roughly 12% TTM pace toward low single digits while net margin stays stuck around the recent 6%-11% range, then I would conclude the compression is structural and the low multiple is deserved. Likewise, if updated cash flow reveals FCF has fallen well below $500M annualized, the 12% yield argument disappears. On the other hand, if NICE can keep quarterly revenue around or above $780M, restore net margin back into the mid-teens, and show cash generation still tracking anywhere near the 2025 level, this stock should not be at $98; a rerating toward even 3x sales or roughly 18x normalized earnings would support something like $130-$145 without requiring an aggressive thesis.
Grok Reading
NICE at $98 and a $5.73B market cap is a profitable, debt-free enterprise software franchise generating roughly $3.07B in trailing revenue and still posting double-digit top-line growth, yet the market is capitalizing it at 14× trailing earnings, under 2× sales, and 6.8× EV/EBITDA. That is not a growth-software multiple; it is a managed-decline multiple. The five-year record is unambiguous: revenue climbed from $1.92B in 2021 to $2.95B in 2025 with a 13.6% CAGR, operating income more than doubled to $646M, and free cash flow hit $698M on a trivial $19M capex base—cash conversion that most software peers would envy. Gross margin holds at 65%, the balance sheet carries zero debt against $379M cash and $3.88B equity, and ROIC sits near 11%. Even after the recent earnings soft patch, the company is still throwing off hundreds of millions in unlevered cash while growing the top line at a recent 12% year-over-year clip. The quantitative models that spit out mid-$200 fair-value estimates are simply reflecting that arithmetic; the gap to $98 is the market’s refusal to believe the cash flows will persist.
What stands out most in the raw numbers is the abrupt margin break in the two most recent quarters. Net income margins that ran 19–20% in the back half of 2025 collapsed to 6.1% and 10.6% in the March and June 2026 periods, dragging trailing twelve-month net income down to roughly $425M from the $612M calendar-2025 print. That is not noise. It is the single hardest data point against a clean compounding story and the clearest quantitative hook for the “AI commoditization / hyperscaler bundle” bear case. Revenue itself did not crack—$782M and $769M quarters are still sequential and year-over-year healthy—so the hit is operating leverage or mix, not demand evaporation. Combined with the fallen-angel narrative and the thesis layer’s concern over contact-center share loss, the market is clearly pricing a scenario in which NICE’s platform becomes a low-growth utility rather than an AI-augmented compounder. I weigh that risk, but I do not give it the full terminal value the current multiple implies: a zero-debt software business with 65% gross margins and historically elite FCF conversion does not usually go to zero just because Microsoft and AWS add chat features.
The strongest counter-argument a skeptic would press is exactly that margin compression plus the secondary signals of market headwinds and a slightly negative thesis score. If the earnings drop is structural—share loss to AI-native entrants, pricing pressure on CCaaS, or failed integration of prior M&A—then the $700M FCF run-rate is already rolling over and the 14× PE is a value trap, not a bargain. The narrative layer’s “fragile fallen-angel” framing captures this cleanly: prior believers have exited, durability of the bull story is low, and modest further misses could keep the stock range-bound or lower. I discount that full bear case because cash-flow quality remains flagged as strong, insider activity is neutral rather than distribution-heavy, revenue confidence is high, and the balance sheet gives management years of runway to reinvest or return capital without distress. A 6–7× EV/EBITDA multiple already embeds a great deal of that permanent impairment; it does not embed a successful stabilization of margins at even mid-teens levels.
What would flip me is straightforward and near-term. Two more quarters of sub-10% net margins with revenue growth slipping under mid-single digits would confirm structural decay and push me to fairly valued or worse at this price. Conversely, a return to 15%+ operating margins and any credible disclosure of AI-attached revenue growth re-accelerating above 12% would make the current $98 entry look like a gift and justify a sharp re-rating toward the $180–220 zone the DCF work already sketches.
Qwen Reading local experiment · off-panel
The number that jumps off the page and that I think the prior models underweight is the 39.3% net income growth in 2025 against a 7.7% revenue growth rate. That gap is not a growth story; it is a cost story. Gross margin actually slipped from 67.7% in 2021 to 66.4% in 2025, so NICE is not pricing its way to higher profitability. The entire 400-basis-point operating-margin expansion (13.7% to 21.9%) is happening below the gross line, which means it is SG&A discipline, headcount optimization, and the kind of one-time or near-one-time cost rationalization that a "fallen angel" label invites. The valuation synthesis spits out a $232 fair value, which implies the market should be paying roughly 22x forward earnings on a company whose revenue is growing at 7.7% and whose margin expansion is structurally finite. I do not get there. At 10.5x trailing P/E, 7x EV/EBITDA, and an 11.9% FCF yield ($697.6M on a $5.88B cap), NICE is cheap by any software-sector yardstick, and the zero-debt balance sheet with $379M in cash and a 1.55 current ratio means the downside is genuinely limited. But "cheap" and "2x in 18 months" are different claims, and the $232 composite is doing a lot of work that the underlying revenue trajectory does not support.
What I find more honest in the data is the five-year arc: revenue has compounded at 11.3%, earnings at 34.9%, and FCF at 14.5%. The earnings CAGR is inflated by the margin story; the FCF CAGR is the cleaner signal, and 14.5% on a zero-debt, 16% ROIC business is solid but not spectacular. The 2024 revenue jump to $2.74B (15.1% YoY) was the best year in the series, and 2025's $2.95B (7.7%) is a sharp deceleration. That single data point is the entire bear case in one number, and I think the market is right to be skeptical. The insider tape is unremarkable — option exercises, a 70,000-share award, a 500-share sale — nothing that signals either insider conviction or insider flight, which is itself a mild negative for a stock the bulls want you to believe is a deep-value rerating.
The strongest case against my own lean toward undervalued is this: if the 39% earnings growth is 80% cost-cutting and 20% organic, then 2026 earnings growth drops to the high single digits, the P/E normalizes to 13-14x on a lower earnings base, and the stock trades flat or lower. A smart opponent would point to the gross-margin erosion, the revenue deceleration, and the fact that NICE's two segments (contact center and financial crime) are both facing AI-native disruption from companies that did not have to carry a legacy on-premises install base. They would also note that the "sector leader" tag in the secondary signals is doing qualitative work that the numbers do not back up — NICE is not growing like a sector leader. I weigh this differently because the FCF conversion is exceptional (operating CF of $716.5M against $612M net income, a 1.17x ratio) and the capex is trivial at $18.9M, meaning the cash the business generates is real and not being consumed by reinvestment. Even if margins normalize back to 2023 levels, NICE still generates roughly $500M in FCF on $2.95B of revenue, which at a 12x multiple on FCF supports a $6B market cap, roughly where we are. The floor is real.
What would change my mind in either direction is the next two quarterly prints. If revenue growth re-accelerates above 12% and management can point to a specific AI product line contributing measurable new ARR, the margin-expansion-skepticism thesis breaks and the stock re-rates toward $130-150 quickly. Conversely, if the next quarter shows revenue growth below 5% and operating margin compresses by even 100 basis points, the "one-time cost story" narrative is confirmed, the 10.5x P/E becomes the ceiling rather than the floor, and I would move to fairly valued or below. The 70,000-share insider award in June is worth watching for the next 90-day lockup expiry — if those shares hit the open, it is a small but telling data point on insider conviction at $100.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
NICE is a mature enterprise software operator that has compounded revenue from $1.92B (2021) to $3.07B (TTM 2026), roughly 10% CAGR, while lifting operating margin from 13.7% to 18.5% (peaked at 20% in 2024). FCF has scaled from $437M to $644M with OCF/NI of 1.85x and negative accruals (-5.3% of assets), Beneish M of -2.64, and Altman Z of 3.61 - all pointing to clean, cash-backed earnings. Net cash of $354.7M and self-funding operations mean survival is not a question. Capital allocation is genuinely shareholder-friendly: diluted shares fell from 66.9M to 61.4M (-2.1% CAGR), with buybacks running 164% of SBC (SBC only ~5% of revenue - modest for software). Insider tape is neutral - mostly option exercises and RSU awards, one trivial $50K sale. What keeps this out of the top tier: gross margin has drifted down four straight years from 68.7% (2022) to 65.1% (TTM), and net income actually stepped back from $439.5M (2024) to $425.4M (TTM) while FCF fell from $797.7M to $644M - a real deceleration after the 2024 peak. Growth is decent but not accelerating, and the moat/competitive position (contact-center / CX software vs. cloud-native disruptors) is not readable from the numbers alone.
Verify before trusting this (5)
- Cause of GM decline from 68.7% to 65.1% - cloud/hosting mix, acquisition amortization, or pricing
- Whether the FCF drop from $797.7M to $644.2M reflects working capital, tax timing, or true deterioration
- Contact-center CX competitive position vs. cloud-native rivals and AI-native entrants
- Cloud/ARR growth vs. legacy on-prem mix and net revenue retention
- Size and dilutive potential of the 98K-share award to executive Russell and total unvested equity overhang
The composite fair value of $217.79 sits roughly 2.2x the $98.04 price, and the signal-adjusted $236.26 is 2.4x - both eye-watering gaps for a profitable, cash-generative software incumbent. I discount the $286 DCF as method drift (terminal-value optimism on a business whose FCF has already rolled over), and I weight the EPV floor of $85 as the downside anchor. The anchored-PE of $213 is the most credible pin; even halving the gap to that number implies fair value comfortably north of $150. Earnings quality is high (score 3), so no haircut is warranted there. The Company-Quality lens grades this Strong (57), which supports the deserved-value case without doing the work on its own. What's priced in at $98: essentially no growth, permanent margin compression, and lingering doubt about M&A digestion and AI disruption to the contact-center franchise. That is a bear-case bundle for a business still generating real cash and buying back stock. Margin of safety looks genuine - price sits near the EPV floor ($85), meaning you're paying roughly for the no-growth business and getting the franchise and optionality free. Not a screaming dislocation (the fallen-angel narrative has teeth - CCaaS competition and rolling margins are real), but the gap is wide enough that Undervalued is the honest call.
Verify before trusting this (5)
- CCaaS segment growth rate and net revenue retention in latest filings
- AI product monetization traction vs revenue cannibalization risk
- Free cash flow trajectory and buyback pace over the last two quarters
- Net debt level post-M&A and interest coverage
- Management guidance on margin trajectory for FY26
The macro tape is roughly neutral (VIX 16.5, S&P just off highs) and NICE's near-zero beta means the broad market barely moves this name mechanically. The pressure is idiosyncratic and narrative-driven: NICE is stuck in a 'fallen-angel' story with fragile durability and low cult support, where the market has lost faith that management can convert AI-platform wins into growth or de-lever the post-M&A balance sheet. That skepticism is visible in the tape reaction to the AOK PLUS win, a legitimate customer proof point that was sold 3.9% on the day. When good news gets sold, sentiment is doing the pushing, not fundamentals. On the other side, momentum readings are constructive and there have been multiple positive customer-win pops in August (Currys, CXone deals), showing the bear narrative is not uncontested and a bull counter-story around AI-agent adoption is trying to form. Net, sentiment leans negative but not violently so: an incumbent enterprise-software name with a fragile narrative in a normalized-multiple cohort, being sold on wins, is under a real headwind, but low beta and improving cash trajectory keep the pressure from becoming dominant.
Verify before trusting this (4)
- Next earnings print reaction: does another beat get sold, confirming the negative sentiment regime, or does the tape start rewarding wins?
- Analyst target revisions and any upgrades tied to AI-agent traction (Cognigy, CXone) that could crack the fallen-angel frame
- Cloud/AI revenue mix disclosure - a visible inflection would let the bull counter-narrative take hold
- Sector rotation into legacy enterprise software vs continued preference for AI-native names
The world is doing two things to NICE at once. Enterprises are spending more, not less, on customer-experience automation — the category is expanding and margins across application software are widening. But the unit of value is migrating from 'seats of software for humans' to 'interactions resolved by machines,' and that migration invites AI-native entrants who do not carry NICE's legacy WFO/on-prem tail. NICE's answer — buying and building conversational/agentic AI and selling it into an installed base of large regulated enterprises (banks, telcos, government) — is credible because switching costs in compliance-heavy contact centers are genuinely high and because recording/financial-crime products are regulatorily sticky. That buys years, not permanence. Meanwhile a 4.83% long rate and a contracting sector demand phase lengthen enterprise sales cycles at the margin. Net: the demand pool grows, NICE participates, but its share of each dollar is contested in a way it was not three years ago.
When we made this prediction on Sep 11, 2026, NICE was $98.29. We expect it to be $128.00 by Mar 2027, and we consider it great value under $105.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Sep 11, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
adjusted_earnings
flips up 25%
cost_of_capital
flips down 25%
shares
flips down 25%